• Svenska
Pipeline

Our science

Novakand Pharma is developing a new class of drugs targeting the fractalkine axis, which consists of the unique ligand-receptor pair CX3CL1-CX3CR1.

Novakand Pharma is developing two fractalkine-blocking candidate drugs, rugocrixan (KAND567) and fosrugocrixan (KAND145). Both are so called receptor antagonists, i.e. they block the fractalkine receptor CX3CR1. The objective is to block certain specific immune cells that are known to be disease promoting in a number of inflammatory conditions and cancer.

Pipeline

Novakand Pharma is a leader in the field of fractalkine blocking drugs and is developing two candidate drugs, rugocrixan (KAND567) and fosrugocrixan (KAND145), both in clinical development stage.

The most advance program is rugocrixan for treatment of ST-elevation myocardial infarction (STEMI). Novakand Pharma has reported positive top-line results from a phase IIa study (FRACTAL) and is now planning to conduct a phase IIb study (FRACTIVE). In addition, positive top-line results have been reported from a phase Ib/IIa study in ovarian cancer (KANDOVA).

Preclinical Research

  • Medicinal Discovery
  • Optimization of Drug Candidates
  • Preparations for Clinical Studies

Clinical Research

  • Clinical Phase I
  • Clinical Phase II
  • Phase III

The transparent fields illustrate ongoing funded projects

Rugocrixan

Project KAND567

Rugocrixan is Novakand Pharma’s lead project with three completed phase II-studies.

The project was acquired from AstraZeneca in pre-clinical stage in 2016. Novakand Pharma has thereafter advanced the project into clinical development and completed six phase I and II studies. As of today, more than 170 healthy subjects and patients have been treated with rugocrixan.

Go to the project

Fosrugocrixan

Project KAND145

Fosrugocrixan is Novakand Pharma’s second generation CX3CR1 antagonist and has been developed solely by the company.

Fosrugocrixan is a so-called pro drug, i.e. it is converted to the active moiety of rugocrixan after administration. Fosrugocrixan has the same mechanism of action as rugocrixan, but certain improved product properties. Novakand Pharma has completed one phase I/first-in-human study with fosrugocrixan in healthy subjects.

Go to the project